OUR APPROACH  
   

 
CyTIX is developing a therapeutic vaccine under the design-concept of “creating cytotoxic T cells specifically activated for all cancer antigens expressed in patient- specific cancer cells”. In order to maximize the specific activity of cytocoxic T cells, we thought that it is important to maximize the antigen-presenting ability of dendritic cells. As such, our development theme was how many cancer antigens can be presented in the MHC Class I.

We have been working on the development of vaccines for treatment with the design concept of making cytotoxic T cells specifically activated for all cancer antigens expressed in patient-specific cancer cells. Therefore, we considered that it is important to maximize the antigen presenting ability of dendritic cells, and developed the theme of how to display the cancer antigen with MHC Class I. The result was the idea of ​​making fusion cells that fused dendritic cells with tumor cells.

Fusion produces one cell, but the resulting fusion cell has the feature that it takes over all the DNA information of the parent cell as a self. In other words, fusion cells that fuse dendritic cells and tumor cells recognize cancer antigens of tumor cells that are the parent cells as self and thus show that they are epoch - making antigen presenting cells that can be presented from MHC class I It was done.

We believe that using this basic technology as a platform, we will be able to lead to the development of therapy for various cancer types.

© Copyright 2017 CyTIX Inc. All rights reserved.